Nasal vaccination using live bacterial vectors

Advanced Drug Delivery Reviews

Volumn 51, Issue 1-3, 2001, Pages 55-69

  Mielcarek, Nathalie ^a   Alonso, Sylvie ^a   Locht, Camille ^a  

^a INSTITUT DE BIOLOGIE DE LILLE   (France)

Author keywords

Attenuation; Bacteria; Heterologous antigens; Immunogenicity; Intranasal; Live vaccine

Indexed keywords

ANTIGENS; BACTERIA; IMMUNIZATION; TISSUE;

INTRANASAL IMMUNIZATION;

VACCINES;

BCG VACCINE; VACCINE;

BACTERIAL COLONIZATION; BORDETELLA PERTUSSIS; EXPRESSION VECTOR; HUMAN; LACTOBACILLUS; LACTOCOCCUS LACTIS; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYSTEM; REVIEW; SALMONELLA; SHIGELLA; STAPHYLOCOCCUS; STREPTOCOCCUS GORDONII; VACCINATION;

ADMINISTRATION, INTRANASAL; ANIMALS; BACTERIA; BCG VACCINE; HUMANS; VACCINES, ATTENUATED; VACCINES, SYNTHETIC;

EID: 0035940316     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(01)00168-5     Document Type: Review

References (107)

1. A recombinant Salmonella typhimurium vaccine induces local immunity by four different routes of immunization
2. Difference between bacterial and food antigens in mucosal immunogenicity
3. Use of green fluorescent protein to tag lactic acid bacterium strains under development as live vaccine vectors
4. Survival, physiology, and lysis of Lactococcus lactis in the digestive tract
5. Chromosomal integration of the green fluorescent protein gene in lactic acid bacteria and the survival of marked strains in human gut simulations
6. Cloning and expression vectors for Lactococci
7. Oral vaccination of mice against tetanus with recombinant Lactococcus lactis
8. Lactococcus lactis: A high level expression of tetanus toxin fragment C and protection against lethal challenge
9. Mucosal immunization with recombinant Lactococcus lactis
10. Lactic acid bacteria as vaccine delivery vehicles
11. Recombinant gram-positive bacteria as vehicles of vaccine antigens
12. Progress in the development of mucosal vaccines based on Lactococcus lactis
13. Lactic acid bacteria as live vaccines
14. Protection against tetanus toxin in mice nasally immunized with recombinant Lactococcus lactis expressing tetanus toxin fragment C
15. Mucosal delivery of murine interleukin-2 (IL-2) and IL-6 recombinant strains of Lactococcus lactis coexpressing antigen and cytokine
16. The potential of Lactobacillus as a carrier for oral immunization: Development and preliminary characterization of vector systems for targeted delivery of antigens
17. Lactic acid bacteria as antigen delivery vehicles for oral immunization purposes
18. Expression of vaccine antigens in Lactobacillus
19. Vaginal immunisation with recombinant gram-positive bacteria
20. Instruments for oral disease-intervention strategies: Recombinant Lactobacillus casei expressing tetanus toxin fragment C for vaccination or myelin proteins for oral tolerance induction in multiple sclerosis
21. Production of cholera toxin B subunit in Lactobacillus
22. Efficient secretion of the model antigen M6-gp41E in Lactobacillus plantarum NCIMB 8826
23. Controlled gene expression systems for lactic acid bacteria: Transferable nisin-inducible expression cassettes for Lactococcus, Leuconostoc, and Lactobacillus spp.
24. Immunoadjuvant activity of oral Lactobacillus casei: Influence of dose on the secretory immune response and protective capacity in intestinal infections
25. Therapeutic role of dietary lactobacilli and lactobacillis fermented dairy products
26. Antibiotic resistance genes in coagulase-negative staphylococci isolated from food
27. Effect of proteolytic starter cultures of Staphylococcus spp. on biogenic amine formation during the ripening of dry fermented sausages
28. Molecular and physiological characterization of dominant bacterial populations in traditional mozzarella cheese processing
29. Development of non-pathogenic staphylococci as vaccine delivery vehicles
30. Isolation and characterization of staphylococci from human skin. I. Amended description of Staphylococcus epidernidis and Staphylococcus saprophyticus and description of three new species: Staphylococcus cohnii, Staphylococcus haemolyticus, and Staphylococcus xylosus
31. Acute pyelonephritis caused by Staphylococcus xylosus
32. Endocarditis caused by Staphylococcus xylosus associated with intravenous drug abuse
33. Staphylococcus carnosus: A new host organism for gene cloning and protein production
34. Engineering of a Staphylococcus carnosus surface display system by substitution or deletion of a Staphylococcus hyicus lipase propeptide
35. Expression of recombinant proteins on the surface of the coagulase-negative bacterium Staphylococcus xylosus
36. Cell surface of recombinant proteins on Staphylococcus carnosus
37. Recombinant Staphylococcus strains as live vectors for the induction of neutralizing anti-diphtheria toxin antisera
38. Cell-surface display of heterologous epitopes on Staphylococcus xylosus as a potential delivery system for oral vaccination
39. Partial protection to respiratory syncytial virus (RSV) elicited in mice by intranasal immunization using live staphylococci with surface-displayed RSV-peptides
40. Surface display of the cholera toxin B subunit on Staphylococcus xylosus and Staphylococcus carnosus
41. Surface display of functional fibronectin-binding domains on Staphylococcus carnosus
42. A surface-displayed cholera toxin B peptide improves antibody responses using food-grade staphylococci for mucosal subunit vaccine delivery
43. Mucosal and serum immunity following commensal enteric colonization
44. Carriage of Neisseria meningitidis and Neisseria lactamica in infants and children
45. Studies on transformation of streptococci
46. Immunization of mice by oral colonization with live recombinant commensal streptococci
47. Commensal bacteria as vectors for mucosal vaccines against sexually transmitted diseases: Vaginal colonization with recombinant streptococci induces local and systemic antibodies in mice
48. Mucosal and systemic immune responses to a recombinant protein expressed on the surface of the oral commensal bacterium Streptococcus gordonii after oral colonization
49. Delivery and expression of a heterologous antigen on the surface of streptococci
50. Human T helper cell recognition of an immunodominant epitope of HIV-1 gp120 expressed on the surface of Streptococcus gordonii
51. Recombinant Streprococcus gordonii as a live vehicle for vaccine antigens
52. Streptococci of dental plaques
53. Pathogenesis of experimental endocarditis
54. Live attenuated Salmonella: A paradigm of mucosal vaccines
55. Mucosal immunogenicity of a recombinant Salmonella typhimurium-cloned heterologous antigen in the absence or presence of coexpressed cholera toxin A2 and B subunits
56. The nature of the attenuation of Salmonella typhimurium strains expressing human papillomavirus type 16 virus-like particles determines the systemic and mucosal antibody responses in nasally immunized mice
57. Construction and characterization of a Salmonella enterica serovar typhimurium clone expressing a salivary adhesin of Streptococcus mutans under control of the anaerobically inducible nirB promoter
58. c expressing urease A and B subunits
59. A lethal role for lipid A in Salmonella infections
60. Constitutive expression of the phoP regulon attenuates Salmonella virulence and survival within macrophages
61. phoP/phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers
62. Oral and rectal immunization of adult female volunteers with a recombinant attenuated Salmonella typhi vaccine strain
63. Safety and immunogenicity in humans of an attenuated Salmonella typhi vaccine vector strain expressing plasmid-encoded hepatitis B antigens stabilized by the Asd-balanced lethal vector system
64. Isolation and characterization of Gal E mutant Ty 21a of Salmonella typhi: A candidate strain for a live, oral typhoid vaccine
65. A controlled field trial of live Salmonella typhi strain Ty 21a oral vaccine against typhoid: Three-year results
66. A murine model of intranasal immunization to assess the immunogenicity of attenuated Salmonella typhi live vector vaccines in stimulating serum antibody responses to expressed foreign antigens
67. Surface-displayed viral antigens on Salmonella carrier vaccine
68. In vivo characterization of the murine intranasal model for assessing the immunogenicity of attenuated Salmonella enterica serovar Typhi strains as live mucosal vaccines and as live vectors
69. Live attenuated Shigella flexneri mutants as vaccine candidates against Shigellosis and vectors for antigen delivery
70. Engineered ΔguaB-AΔvirG Shigella flexneri 2a strain CVD 1205: Construction, safety, immunogenicity, and potential efficacy as a mucosal vaccine
71. Further characterization of ΔaroAΔvirG Shigella flexneri 2a strain CVD 1203 as a mucosal Shigella vaccine and as a live-vector vaccine for delivering antigens of enterotoxigenic Escherichia coli
72. Immunogenicity of IpaC-hybrid proteins expressed in the Shigella flexneri 2a vaccine candidate SC602
73. Induction of a local anti-IpaC antibody response in mice by use of a Shigella flexneri 2a vaccine candidate: Implications for use of IpaC as a protein carrier
74. ΔguaBA attenuated Shigella flexneri 2a strain CVD 1204 as a Shigella vaccine and as a live mucosal delivery system for fragment C of tetanus toxin
75. The history of BCG
76. New use of BCG for recombinant vaccines
77. Immune responses induced by BCG recombinant for human papillomavirus L1 and E7 proteins
78. The kinetics of specific immune responses in rhesus monkeys inoculated with live recombinant BCG expressing SIV Gag, Pol, Env, and Nef proteins
79. Immunogenicity of recombinant BCG producing the GRA1 antigen from Toxoplasma gondïi
80. BCG expressing LCR1 of Leishmania chagasi induces protective immunity in susceptible mice
81. Long-lasting protective immunity against rodent malaria parasite infection at the blood stage by recombinant BCG secreting merozoite surface protein-1
82. Systemic and mucosal immunity induced by BCG vector expressing outer-surface protein A of Borrelia burgdorferi
83. Protective humoral response against pneumococcal infection in mice elicited by recombinant bacille Calmette-Guérin vaccines expressing pneumococcal surface protein A
84. Effective immunization against cutaneous leishmaniasis with recombinant bacille Calmette-Guérin expressing the Leishmania surface proteinase gp63
85. Protective immune responses induced by secretion of a chimeric soluble protein from a recombinant Mycobacterium bovis bacillus Calmette-Guérin vector candidate vaccine for human immunodeficiency virus type 1 in small animals
86. Humoral and cellular immune responses in mice immunized with recombinant Mycobacterium bovis bacillus Calmette-Guérin producing a pertussis toxin-tetanus toxin hybrid protein
87. A new series of mycobacterial expression vectors for the development of live recombinant vaccines
88. Protection of monkeys against airborne tuberculosis by aerosol vaccination with bacillus Calmette-Guérin
89. Aerogenic BCG vaccination against tuberculosis in animal and human subjects
90. Protective immunity elicited by recombinant Bacille Calmette-Guérin (BCG) expressing outer surface protein A (OspA) lipoprotein: A candidate Lyme disease vaccine
91. Systemic and mucosal immune responses after intranasal administration of recombinant Mycobacterium bovis bacillus Calmette-Guérin expressing glutathione S-transferase from Schistosoma haematobium
92. Neutralizing antibody responses elicited in mice immunized with recombinant bacillus Calmette-Guérin producing the Schistosoma mansoni glutathione S-transferase
93. Recombinant bacille Calmette-Guérin expressing the measles virus nucleoprotein protects infant rhesus macaques from measles virus pneumonia
94. Induction of mucosal immune responses against a heterologous antigen fused to filamentous hemagglutinin after intranasal immunization with recombinant Bordetella pertussis
95. Homologous and heterologous protection after single intranasal administration of live attenuated recombinant Bordetella pertussis
96. A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis
97. Molecular aspects of Bordetella pertussis pathogenesis
98. The filamentous haemagglutinin, a multifaceted adhesion produced by virulent Bordetella spp.
99. Bordetella pertussis filamentous hemagglutinin enhances the immunogenicity of liposome-delivered antigen administered intranasally
100. Intranasal priming with recombinant Bordetella pertussis for the induction of a systemic immune response against a heterologous antigen
101. Local transient induction of inflammatory cytokines after intranasal administration of recombinant Bordetella pertussis
102. Construction and characterization in vivo of Bordetella pertussis aroA mutants
103. Pertussis toxin: Structure-function relationship
104. Characterization of murine lung inflammation after infection with parental Bordetella pertussis and mutants deficient in adhesins or toxins
105. Responses to Bordetella pertussis mutant strains and to vaccination in the coughing rat model of pertussis
106. Genital antibody responses in mice after intranasal infection with an attenuated candidate vector strain of Bordetella pertussis
107. Live bacterial vectors for intranasal delivery of protective antigens